gracellbio.com - GRCL Enterprise Value-to-Sales Ratio

Public company logo of Gracell Bio (GRCL)

Gracell Biotechnologies operates under severe geopolitical pressure and regulatory barriers between China and the West. The business value-to-revenue ratio on GURU.Markets visualizes the valuation trend, where the level reflects the current magnitude of the metric. Market capitalization relies on the development of CAR-T therapy for lymphomas, which Gracell Biotechnologies seeks to accelerate through integration into a global pharmaceutical holding.

gracellbio.com (GRCL): Enterprise Value-to-Revenue Ratio from 07/04/2022 to 11/20/2026

Financial and market metric breakdowns for Gracell Biotechnologies Ltd (GRCL)

Fundamental valuation:Gracell Biotechnologies (GRCL)
Core merchandise of Gracell Bio

Through the FasTCAR platform, Gracell Biotechnologies (GRCL) has radically optimized its unit economics and CAR-T cell production speed, which directly impacts its revenue generation potential. This price-to-sales ratio reflects the market valuation of the business excluding debt load, allowing investors to determine the extent of the premium paid for current sales scales and assess the sustainability of the capitalization amid changes in operating flows.